Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel targeted therapies for eosinophil-associated diseases and allergy.

Literature DB >> 25340931

Novel targeted therapies for eosinophil-associated diseases and allergy.

Susanne Radonjic-Hoesli¹, Peter Valent, Amy D Klion, Michael E Wechsler, Hans-Uwe Simon.

Abstract

Eosinophil-associated diseases often present with life-threatening manifestations and/or chronic organ damage. Currently available therapeutic options are limited to a few drugs that often have to be prescribed on a lifelong basis to keep eosinophil counts under control. In the past 10 years, treatment options and outcomes in patients with clonal eosinophilic and other eosinophilic disorders have improved substantially. Several new targeted therapies have emerged, addressing different aspects of eosinophil expansion and inflammation. In this review, we discuss available and currently tested agents as well as new strategies and drug targets relevant to both primary and secondary eosinophilic diseases, including allergic disorders.

Entities: Chemical

Keywords: asthma; biologicals; chronic eosinophilic leukemia; hypereosinophilic syndrome; tyrosine kinase inhibitors

Mesh：

Substances：
Anti-Allergic Agents

Year: 2014 PMID： 25340931 PMCID： PMC4924608 DOI： 10.1146/annurev-pharmtox-010814-124407

Source DB: PubMed Journal: Annu Rev Pharmacol Toxicol ISSN： 0362-1642 Impact factor: 13.820

154 in total

1. IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist.

Authors: Rebecca E Slager; Gregory A Hawkins; Elizabeth J Ampleford; Alexandra Bowden; Lauren E Stevens; Matthew T Morton; Adrian Tomkinson; Sally E Wenzel; Malinda Longphre; Eugene R Bleecker; Deborah A Meyers
Journal: J Allergy Clin Immunol Date: 2010-10 Impact factor: 10.793

2. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

Authors: D W MacGlashan; B S Bochner; D C Adelman; P M Jardieu; A Togias; J McKenzie-White; S A Sterbinsky; R G Hamilton; L M Lichtenstein
Journal: J Immunol Date: 1997-02-01 Impact factor: 5.422

3. The regulation of normal and leukemic hematopoietic stem cells by niches.

Authors: Meng-Meng Huang; Jiang Zhu
Journal: Cancer Microenviron Date: 2012-07-22

4. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors: Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245

5. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.

Authors: Stephan von Gunten; Monique Vogel; Alexander Schaub; Beda M Stadler; Sylvia Miescher; Paul R Crocker; Hans-Uwe Simon
Journal: J Allergy Clin Immunol Date: 2007-03-02 Impact factor: 10.793

6. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Authors: Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu
Journal: Nat Immunol Date: 2002-06-10 Impact factor: 25.606

Review 7. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.

Authors: J Gotlib; J Cools
Journal: Leukemia Date: 2008-10-09 Impact factor: 11.528

8. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

Authors: Jennifer K Garrett; Sean C Jameson; Blythe Thomson; Margaret H Collins; Lynne E Wagoner; Debbie K Freese; Lisa A Beck; Joshua A Boyce; Alexandra H Filipovich; Joyce M Villanueva; Steven A Sutton; Amal H Assa'ad; Marc E Rothenberg
Journal: J Allergy Clin Immunol Date: 2003-12-12 Impact factor: 10.793

Review 10. Eosinophils in skin diseases.

Authors: Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal: Semin Immunopathol Date: 2021-06-07 Impact factor: 9.623

Novel targeted therapies for eosinophil-associated diseases and allergy.

1. IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist.

2. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

3. The regulation of normal and leukemic hematopoietic stem cells by niches.

4. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

5. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.

6. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Review 7. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.

8. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

9. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.

10. The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells.

Review 1. Biological therapies for eosinophilic gastrointestinal diseases.

Review 2. Biologic therapies targeting eosinophils: current status and future prospects.

Review 3. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

4. RhoH is a negative regulator of eosinophilopoiesis.

Review 5. The eosinophil: For better or worse, in sickness and in health.

Review 6. Novel Therapies for Eosinophilic Disorders.

7. Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China.

Review 8. The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020.

Review 9. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.

Review 10. Eosinophils in skin diseases.